Please assess the completion status of the following clinical trial:

Trial Title: A Single Arm, Open-label,Phase Ib Study of CT053PTSA in Preciously Treated Patients With Advanced and Metastatic RCC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed renal cell cancer.Patients must be diagnosed with advanced or metastatic disease,disease progressed to previous treatment .~* Measurable disease according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)~* Toxicity recovered to NCI CTCAE v.4.03 Grade ≤1 from previous treatments (except alopecia)~* ECOG performance status (PS) 0 or 1~* Life expectancy of ≥ 12 weeks~* Adequate organ function~* Voluntary agreement to provide written informed consent and the willingness and ability to comply with all aspects of the protocol~Exclusion Criteria:~* Chemotherapy,radiotherapy,immunotherapy and targeted therapy less than 4 months prior to administration.~* Symptomatic, untreated or unstable central nervous system metastases~* Uncontrolled hypertension that require anti-hypertensive agents to control, or systolic blood pressure (BP) \>140mmHg or diastolic BP \>90 mmHg before the first administration (BP is the mean blood pressure of two measures that 1 hours interval or above)~* Doppler ultrasound evaluation：Left ventricular ejection fraction \< 50%~* Significantly clinical arrhythmia or symptomatic bradycardia, or male with QTCF \> 450 ms or female with QTCF \> 470 ms, or patients with a history of torsion or congenital QT prolonged syndrome long QT syndrome~* Certain factors that would preclude adequate absorption of CT053PTSA and gefitinib (eg. unable to swallow, chronic diarrhea, intestinal obstruction)~* Patients with evidence of bleeding tendency, including the following cases: gastrointestinal bleeding, hemorrhagic gastric ulcer, fecal occult blood ++ and above; or melena or hematemesis within 2 months; or visceral bleeding that may occur considered by investigator~* History of organ transplantation~* Any disease of the following bellowed within 12 months prior to administration: Myocardial infarction, severe angina, or unstable angina, coronary or peripheral artery bypass graft, congestive heart failure~* Pulmonary embolism or cerebrovascular events (including transient ischemic attack)within 6 months prior to administration~* Infection of HIV~* Patients with infection of HBV or HCV. Patients with positive of HBsAg or HBcAb,and HBV-DNA can be measured (\>500IU/ml). Patients with positive of anti-HCV,and HCV-RNA can be measured by PCR.~* Other malignancies within 5 years prior to enrollment, with the exception of carcinoma in situ of the cervix, basal or squamous cell skin cancer~* Pregnant or lactating woman~* Any other reason the investigator considers the patient is not suitable to participate in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- CT053PTSA (Type: EXPERIMENTAL): 60-100mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy